There has been accumulating evidence showing that downregulation of WWOX expression promotes tumor development in various cancer types.[8] In breast and ovarian cancers, reduced WWOX expression drove metastatic progression by triggering the signaling pathways involving JNK/STAT3 activation, TGF‐β‐mediated SMAD phosphorylation, and Myc‐dependent transcriptional reprogramming, thereby facilitating coordinated epithelial‐mesenchymal transition (EMT) and extracellular matrix remodeling.[9, 10, 11, 12, 13] Husanie et al. Here, WWOX is linked to ovarian carcinoma.